Trial Profile

A Phase IIa trial investigating AB-101a in AD patient

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 101 Alphyn Biologics (Primary)
Indications Atopic dermatitis
Focus First in man; Therapeutic Use
Sponsors Alphyn Biologics

Most Recent Events

04 Nov 2024 According to an Alphyn Biologics media release, primary endpoint of this study has been met.
27 Aug 2024 According to an Alphyn Biologics media release, data from this trial will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam, September 25-28, 2024.
22 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com